Long-Term Liabilities to Equity: mereobiopharma.com (MREO)

Official company branding of Mereo BioPharma Group plc (MREO)

Mereo BioPharma develops therapies for the treatment of hereditary skeletal pathologies, protecting its market share with antibody patents. The firm's strategy relies on acquiring promising projects from industry leaders for final development. The confirmed price history on the (separate_debt_long_eq) chart reflects a value of 0.00. Business stability is ensured by agreements with major distributors, which guarantee the sale of orphan drugs.

mereobiopharma.com (MREO): Long-Term Debt to Capital from 07/04/2022 to 10/29/2026

Comprehensive metric breakdowns and analytics for Mereo BioPharma Group (MREO)

- price and consensus price forecast:
Market Chart Mereo BioPharma Group PLC|MREO - Price Target Chart
- market capitalization data:
Market Valuation Mereo BioPharma Group plc|MREO - Enterprise Value
- book capitalization data:
Net Asset Value per Share Mereo BioPharma|MREO - Book Capitalization|Market Cap to Net Assets Ratio mereobiopharma.com|MREO - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Coefficient Mereo BioPharma|MREO - Long-Term Debt to Capital|Short-Term Debt to Capital Mereo BioPharma Group PLC|MREO - Company Debts|Debt to Book Capitalization Ratio Mereo BioPharma Group plc|MREO - Company Long-Term Debts|Short-Term Debt Volume Mereo BioPharma
Comprehensive company analysis:MREO, mereobiopharma.com
Core merchandise of Mereo BioPharma Group

Developing drugs for the treatment of rare pathologies requires Mereo BioPharma (MREO) to make significant capital investments, making the control of long-term debt critical for maintaining financial independence. This indicator measures the volume of loans with a maturity of over one year relative to equity, allowing for an assessment of stress resilience and default risk through the ratio of long-term borrowed capital to equity.

Direct competitors

Ratio of Long-Term Indebtedness to Capital VRTX|ALNY - Long-Term Debt to Equity|Long-Term Liabilities to Equity Insmed Corp (INSM)|UTHR: Long-Term Debt to Capital|Long-Term Liabilities to Capital biomarin.com BMRN|BBIO: Long-Term Debt to Capital|BGM - Long-Term Debt to Equity Ratio|Cogent Bio - Long-Term Debt to Capital|Xeris Pharma (XERS) - Ratio of Long-Term Indebtedness to Capital|KROS (Keros Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital ARCT|Long-Term Debt to Equity Eton Pharmaceuticals, Inc. (ETON)|Long-Term Debt to Equity Kamada Ltd (KMDA)|Long-Term Debt to Capital FULC|ABEO - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio Protalix BioTherapeutics|PLRX - Long-Term Liabilities to Equity|Long-Term Debt to Capital APLT|Rein Therapeutics Inc. (RNTX) - Long-Term Liabilities to Capital|Long-Term Debt to Capital Gelteq Ltd (GELS)|Long-Term Debt to Capital Ratio Aytu Therapeutics (AYTU)|Chemomab Therapeutics (CMMB) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient SRXH (srxhealth.com)|Polyrizon (PLRZ) - Long-Term Debt to Equity|Long-Term Liabilities to Equity Aeterna Zentaris Inc AEZS|Long-Term Debt to Capital CTD Holdings (CYTH)|INZY - Long-Term Debt to Capital Coefficient|RPHM: Long-Term Debt to Capital|CSCI (cosciensbio.com) - Long-Term Debt to Capital